Telitacicept 160 mg

BIOLOGICAL2 trials

Sponsors

RemeGen Co., Ltd.

Conditions

Lupus NephritisPrimary Sjogren's Syndrome

Phase 2

A Study of Telitacicept in Lupus Nephritis

RecruitingNCT05680480

RemeGen Co., Ltd.Lupus Nephritis

Start: 2023-04-17End: 2026-01-31Target: 120Updated: 2024-09-23

Phase 3

A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome

CompletedNCT05673993

RemeGen Co., Ltd.Primary Sjogren's Syndrome

Start: 2023-04-06End: 2025-05-06Updated: 2025-10-01

Related Papers

Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial

Annals of the Rheumatic Diseases2023-12-21107 citations